Biopharmaceutical company Acceleron Pharma Inc (NASDAQ:XLRN) revealed on Friday the election of Robert K. Zeldin, MD as chief medical officer (CMO).
In the senior position, Dr Zeldin succeeds the company's outgoing CMO, Matthew Sherman, MD, who will remain until the anticipated mid-2018 release of topline Phase 3 data from the BELIEVE trial of luspatercept in beta-thalassemia patients and will then serve in an advisory capacity for one year thereafter.
Most recently, Dr Zeldin has served as CMO as well as a member of the Executive Committee at Belgium-based Ablynx NV, with responsibility for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics and Data Management functions and led a team of 60.
Previously, Dr Zeldin was employed as senior vice president and head of Global Clinical Development at French pharmaceutical firm Stallergenes SA, vice president and US medical franchise head, Respiratory and Dermatology at Novartis Pharmaceuticals as well as senior director of Clinical Development in worldwide regulatory affairs and clinical development in the respiratory, cardiovascular and infectious disease therapeutic areas at Merck.
Earlier in his career, Dr Zeldin was a medical officer at the US Food & Drug Administration's Center for Biologics Evaluation and Research.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer